We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Two Genes Linked to Risk of Gallbladder Cancer

By LabMedica International staff writers
Posted on 14 Mar 2017
By performing a genome-wide scan (GWAS) of gallbladder cancer patients and hospital visitor controls, a team of researchers identified two genes that were associated with a small but definite risk of developing the disease.

Gallbladder cancer is highly lethal, with notable differences in incidence by geography and ethnic background. More...
A team comprising investigators from Johns Hopkins University, the [U.S.] National Cancer Institute and Tata Memorial Cancer Centre performed a genome-wide scan of gallbladder cancer cases and hospital visitor controls, both of Indian descent.

To carry out the study, the investigators collected blood samples from 1,042 patients who were treated in Mumbai between September 2010 and June 2015. They also collected blood samples during this time from 1,709 healthy volunteers matched by age, sex, and geographic origin with no known cancers who were visiting patients at the hospital. Thus, the discovery cohort comprised 1042 gallbladder cancer cases and 1709 controls while a replication cohort collected in 2015 and 2016 contained 428 gallbladder cancer cases and 420 controls.

The investigators examined three of the most significant single-nucleotide polymorphisms (SNPs) in the replication cohort and did a meta-analysis of the GWAS discovery and replication sets to get combined estimates of association.

Results revealed genome-wide significant associations for several markers in the chromosomal region 7q21.12 harboring both the ABCB1 (ATP-binding cassette sub-family B member 1) and ABCB4 (ATP binding cassette subfamily B member 4) genes. These genes are known to be involved in moving lipids through the liver, gallbladder, and bile ducts, and a previous study had associated ABCB4 with the formation of gallstones, a known risk factor for gallbladder cancer.

"Gallbladder cancer, like many other cancers and complex diseases, is likely to be associated with many genetic markers, each of which may have small effects, but in combination they can explain substantial variation in risk," said contributing author Dr. Nilanjan Chatterjee, professor of oncology and biostatistics at John Hopkins University. "Using the latest technologies to look at the causes – notably the genetic underpinnings – of this understudied disease just makes a lot of sense."

The study was published in the March 5, 2017, online edition of the journal The Lancet Oncology.


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.